Quotes 5-day view Delayed Xetra
03/01/2021
03/02/2021
03/03/2021
03/04/2021
03/05/2021
Date
35.93(c)
35.84(c)
35.5(c)
35.97(c)
36.03(c)
Last
1 526 596
1 668 416
1 402 094
1 489 104
1 451 463
Volume
+1.38%
-0.25%
-0.95%
+1.32%
+0.17%
Change
Sales 2020
36 158 M
43 067 M
43 067 M
Net income 2020
1 735 M
2 067 M
2 067 M
Net Debt 2020
23 519 M
28 014 M
28 014 M
P/E ratio 2020
11,4x
Yield 2020
2,23%
Sales 2021
36 834 M
43 873 M
43 873 M
Net income 2021
1 768 M
2 106 M
2 106 M
Net Debt 2021
21 660 M
25 800 M
25 800 M
P/E ratio 2021
11,4x
Yield 2021
2,35%
Capitalization
20 088 M
23 932 M
23 927 M
EV / Sales 2020
1,21x
EV / Sales 2021
1,13x
Nbr of Employees
311 269
Free-Float
72,0%
Fresenius SE & Co. KGaA specializes in designing, producing, and selling medical drugs, equipment, and devices used in clinical hospitalization and at home. Net sales break down by activity as follows:
- dialysis treatment (49.2%; Fresenius Medical Care): sales of equipment for hemodialysis, pediatric dialysis, peritoneal dialysis, dialysis services, etc.;
- hospital administration and engineering (31.4%;...
Notations Surperformance© of Fresenius SE & Co. KGaA
Trading Rating :
Investor Rating :
All news about FRESENIUS SE & CO. KGAA
News in other languages on FRESENIUS SE & CO. KGAA
Analyst Recommendations on FRESENIUS SE & CO. KGAA
Italy looks to safeguard biomedical valley leading fight against COVID-19
Chart FRESENIUS SE & CO. KGAA
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends FRESENIUS SE & CO. KGAA
Short Term Mid-Term Long Term Trends Bearish Neutral Neutral
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
21
Average target price
45,55 €
Last Close Price
36,03 €
Spread / Highest target
88,7%
Spread / Average Target
26,4%
Spread / Lowest Target
-51,0%
Please enable JavaScript in your browser's settings to use dynamic charts.